The FDA has granted accelerated approval to sevabertinib (Hyrnuo), for previously treated HER+ metastatic non-squamous ...

The FDA has approved ziftomenib (KOMZIFTI), the first oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). In the KOMET-001 trial, the therapy ...

The FDA has approved epcoritamab-bysp (Epkinly) with rituximab and lenalidomide for relapsed or refractory follicular ...

Novartis has opened a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California, ...

The Phase III SUNMO trial could mark a breakthrough for transplant-ineligible patients with relapsed or refractory large B-cell lymphoma. In this ONCOLife interview, we spoke with Dr. Jason Westin, ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted two positive opinions for Merck’s anti–PD-1 therapy pembrolizumab (KEYTRUDA®), potentially expanding ...

AbbVie has announced plans to acquire Nimble Therapeutics in a $200 million deal. The acquisition brings Nimble’s pioneering oral peptide IL23R inhibitor, currently in preclinical development for ...

Results from the phase III evERA trial show that giredestrant in combination with everolimus significantly prolonged progression-free survival in ER+, HER2- advanced breast cancer following prior CDK4 ...

Zymeworks Inc. announced that the United States Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for ZW171. This novel bispecific antibody targets ...

The U.S. Food and Drug Administration (FDA) has approved Thermo Fisher’s Oncomine Dx Target Test, a next-generation sequencing (NGS)-based companion diagnostic, to identify patients eligible for ...

Everest Medicines' licensing partner Calliditas Therapeutics announced that the FDA approved Nefecon to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) at ...